GlassScriptPhysician profile
Kristi Dougan
NPI 1275993149
$5,196.13
in general payments reported to CMS, 2019-2025
26 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.97 · 2022: $420 · 2023: $1,679 · 2024: $1,368 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,323.45 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $832.24 | 2022-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $634.80 | 2022-2025 | Relistor |
| Pfizer INC. | $441.33 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $404.62 | 2023-2025 | Horizant, Horizant |
| Idorsia Pharmaceuticals US INC | $359.71 | 2022-2024 | Quviviq |
| Forte Bio-Pharma LLC | $152.71 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $152.52 | 2023-2025 | Ztlido |
| Virtus Pharmaceuticals LLC | $141.76 | 2023-2025 | Levorphanol Tartrate |
| Merck Sharp & Dohme LLC | $114.22 | 2023 | Belsomra |
| Vertex Pharmaceuticals Incorporated | $72.19 | 2024-2025 | |
| Valinor Pharma, LLC | $71.99 | 2025 | Movantik |
| Biohaven Pharmaceutical Holding Company LTD. | $56.15 | 2022 | |
| Masimo Corporation | $56.10 | 2023 | Na |
| Spr Therapeutics, INC | $49.82 | 2025 | Sprint Pns System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $46.38 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Almatica Pharma LLC | $45.60 | 2023 | Gralise |
| Arbor Pharmaceuticals, INC. | $42.28 | 2021-2022 | |
| Ibsa Pharma INC. | $42.25 | 2023-2025 | Tirosint, Licart, Flector |
| Hikma Pharmaceuticals USA | $38.74 | 2022-2024 | Kloxxado |
| Uswm, LLC | $30.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.99 | 2021 | |
| Novo Nordisk INC | $18.05 | 2021 | |
| Abbott Laboratories | $15.73 | 2025 | Eterna |
| Mml US, INC. | $14.97 | 2023 | Reactiv8 |
| Janssen Biotech, INC. | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Dougan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.